Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.
|
Jun 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
|
Jan 2019
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS
|
Jun 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Expression of nucleoside metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
|
Nov 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
|
Mar 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
|
Sep 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS
|
Jun 2020
|
Leukemia
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
|
Feb 2018
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL)
|
Jun 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia
|
Mar 2021
|
Leukemia
|
aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH)
|